ClinicalTrials.gg
RecruitingNCT07686120BaxNoDUpdated Oct 15, 2026

A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.

A Phase 3 interventional study of baxdrostat 2mg and Placebo 2mg in Uncontrolled Hypertension, sponsored by AstraZeneca. Recruiting at 51 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 15, 2026Now RecruitingFirst site in China+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
286
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing baxdrostat in Hypertension — 2 open to participants now, 4 under way, 3 of them phase 3. baxdrostat · Hypertension.

Planned enrollment
5th of 18
286 · median 197
Started
2026
the only one that year
Phase 3
6 of 18
2 open now
Registered
18th of 18
by date
Lead sponsor
16 of 18
AstraZeneca

Among the 18 studies testing baxdrostat in Hypertension, this one is the 5th largest by planned enrollment, is the only one that started in 2026, is one of 6 in phase 3, and was the 18th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 18 studies testing baxdrostat in Hypertension are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About baxdrostat

baxdrostat: first FDA approval 2026 (BAXFENDY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baxdrostat in Hypertension, or all of them as a file.
02

Study summary

This is a Phase IIIb, multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of baxdrostat 2mg versus placebo, administered QD orally, on the reduction of ambulatory 24-hour average SBP in participants with uHTN.

Consenting participants will be screened within 4 weeks and will subsequently enter a 4-week run-in period with placebo. Thereafter, participants will be randomised in a 1:1 ratio to receive one of the following 2 treatments QD, during a 12-week double-blind treatment period:

baxdrostat 2mg Placebo The randomisation will be stratified by mean ambulatory SBP at baseline (\<140 mmHg, ≥140 mmHg) and the number of background antihypertensive medication classes (2, ≥3) at baseline.

During the 12-week double-blind treatment period, participants should remain on their background antihypertensive medication. Doses of background medications should not be changed during this period unless participants experience SBP \< 100 mmHg with symptoms of hypotension. Rescue therapy is permitted if the SBP or DBP exceeds 170 or 105 mmHg, respectively. The choice of rescue therapy is based on the Investigator's best clinical judgement; however, the use of potassium-sparing diuretics and MRAs are prohibited.After completing the 12 weeks double-blind treatment period participants will complete a 2-week safety follow-up period. The total duration of study participation will be of approximately 22 weeks.

Read the detailed description

This is a Phase IIIb, multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of baxdrostat 2mg versus placebo, administered QD orally, on the reduction of ambulatory 24-hour average SBP in participants with uHTN, defined as BP targets not being achieved in an individual despite a stable regimen of ≥2 antihypertensive agents from different therapeutic classes (at full doses per guidelines or maximum tolerated dose in the judgement of the Investigator), none of which is a diuretic.

Consenting participants will be screened within 4 weeks and will subsequently enter a 4-week run-in period with placebo. Thereafter, participants will be randomised in a 1:1 ratio to receive one of the following 2 treatments QD, during a 12-week double-blind treatment period:

baxdrostat 2mg Placebo The randomisation will be stratified by mean ambulatory SBP at baseline (\<140 mmHg, ≥140 mmHg) and the number of background antihypertensive medication classes (2, ≥3) at baseline.

During the 12-week double-blind treatment period, participants should remain on their background antihypertensive medication. Doses of background medications should not be changed during this period unless participants experience SBP \< 100 mmHg with symptoms of hypotension. Rescue therapy is permitted if the SBP or DBP exceeds 170 or 105 mmHg, respectively. The choice of rescue therapy is based on the Investigator's best clinical judgement; however, the use of potassium-sparing diuretics and MRAs are prohibited.

After completing the 12 weeks double-blind treatment period participants will complete a 2-week safety follow-up period. The total duration of study participation will be of approximately 22 weeks.

The study is planned to be conducted in approximately 50 study sites across China.

A Data Monitoring Committee will be appointed for this study to monitor the safety and scientific integrity of a human research intervention and to make recommendations to AstraZeneca regarding the stopping of a study due to any harm.

An Executive Committee will be formed to provide scientific oversight and confirmation of the overall study design, of CSP and any protocol amendments (If appliable).

03

Conditions studied

  • Uncontrolled Hypertension

Browse trials for

Keywords

  • Uncontrolled Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

Age 1. Participant must be ≥18 years old, at the time of signing the .

Type of Participant and Disease Characteristics

  1. Mean seated SBP on AOBPM ≥140 mmHg and \<170 mmHg at screening. Seated BP will be measured using standardised automated BP machines and using standardised procedures.
  2. Have a stable regimen (≥ 4 weeks before the screening visit) of ≥ 2 antihypertensive medications, from different therapeutic classes (should not be a diuretic), at full doses per guidelines or maximum tolerated doses in the judgement of the Investigator, for at least 4 weeks prior to screening (participants who do not meet this criterion may be rescreened at the Investigator's discretion. Beta blockers used to treat other conditions (i.e., migraine, heart failure [HF], coronary artery disease) should not be counted as an antihypertensive medication for the purpose of qualifying for this study.
  3. Have ≥45 mL/min/1.73m2 at screening.
  4. Serum potassium (K+) level ≥3.5 and \<5.0 mmol/L at screening, determined as per central laboratory.

    Sex and /Barrier Requirements

  5. Only female participants:

    Contraceptive use by females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    a) Female participants: i. Females not of are defined as females who are either permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are . Females will be considered postmenopausal if they have been amenorrhoeic for 12 months prior to the planned date of randomisation without an alternative medical cause. The following age specific requirements apply:

    • Women \<50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and follicle-stimulating hormone levels within the postmenopausal range.
    • Women ≥50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatment ii. Female participants of child-bearing potential must use one highly effective form of birth control. A highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly. Females of child-bearing potential who are sexually active with a non-sterilised male partner must agree to use one highly effective method of birth control, as defined below, from 30 days before enrolment and throughout the study, and until at least 30 days after last dose of study intervention. Cessation of contraception after this point should be discussed with a responsible physician.

    iii. The following are not acceptable methods of contraception: periodic abstinence (calendar, symptom-thermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only and lactational amenorrhoea. Female condom and male condom should not be used together.

    iv. All females of child-bearing potential must have a negative pregnancy test result at screening and not be at stage of breastfeeding v. Highly effective birth control methods include: Total sexual abstinence is an acceptable method provided it is the usual lifestyle of the participant (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments) ([periodic abstinence - e.g., calendar, ovulation, sympto-thermal, post-ovulation methods - declaration of abstinence for the duration of exposure to study intervention and withdrawal are not acceptable methods of contraception]); a vasectomised partner; subdermal contraceptive implants; bilateral tubal occlusion; intrauterine device/levonorgestrel intrauterine system; injectable contraceptive; oral contraceptive associated with inhibition of ovulation; and contraceptive transdermal patch, or vaginal ring.

    Informed Consent

  6. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

    5.1.1 Randomisation Criteria

    Participants are eligible to be randomised to a treatment group only if all the following criteria apply:

  7. Ambulatory 24-hour average SBP ≥130 mmHg.
  8. Have an 80% to 120% adherence to placebo during the Run-in period, based on pill counts on the morning of randomization. Adherence will be derived for each patient based on pill counts as the number of pills taken (dispensed - returned), divided by the expected number of pills taken.
  9. Have no change in background therapy regimen and dose consisting of ≥ 2 antihypertensive medications (none of which is a diuretic), for at least 4 weeks prior to randomisation. Beta-blockers used to treat other conditions (i.e., migraine, HF, coronary artery disease) should not be counted as an antihypertensive medication for the purpose of qualifying for this study.
  10. Demonstrated good adherence to the prescribed antihypertensive medications by performing DOT.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

Medical Conditions

  1. As judged by the investigator, any evidence of which in the investigator's opinion makes it undesirable for the participant to participate in the study.
  2. Mean seated SBP on AOBPM ≥170 mmHg (participants who do not meet this criterion may be rescreened at the Investigator's discretion, see Section 5.4.2 for rescreening criteria and Section 8.2.1 for BP measurement procedures).
  3. Mean seated DBP on AOBPM ≥110 mmHg (participants who do not meet this criterion may be rescreened at the Investigator's discretion).
  4. Serum sodium level (Na+) \<135 mmol/L at screening, determined as per central laboratory.
  5. Has the following known secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation.
  6. functional HF class IV at Screening.
  7. Medical history of stroke, acute coronary syndrome, hypertensive encephalopathy, or hospitalization for HF within 6 months prior to Screening.
  8. Planned percutaneous coronary intervention/coronary artery bypass grafting or percutaneous coronary intervention/coronary artery bypass grafting done within 6 months prior to screening.
  9. Known current severe left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy and/or severe aortic valvular disease.
  10. Known severe hepatic impairment, defined as Class C, based on records that confirm documented medical history.
  11. Uncontrolled diabetes with >10.0% (86 mmol/mol) at Screening.
  12. Participants suspected to have severe cardiac hypertrophy.
  13. Participants who are pregnant or breastfeeding. Prior/Concomitant Therapy
  14. Simultaneous use of angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs) or angiotensin receptor-neprilysin inhibitor (ARNI) in current or prior treatment within the 4 weeks before screening
  15. Prior medical treatment with any MRAs, antiarrhythmic medications (beta blockers and calcium channel blockers classified as Class II/IV antiarrhythmics used to treat hypertension, and digoxin are permitted), direct renin inhibitor, thiazide diuretic, loop diuretic, potassium-sparing diuretic, or other diuretics use within 4 weeks prior to screening.
  16. Is expected to receive or is receiving any herbal anti-hypertensive medicine or antihypertensive medication of unknown ingredients.
  17. Treatment with potassium binders within 1 month prior to screening.
  18. Is expected to receive or is receiving any of the exclusionary drugs such as strong inducers of cytochrome P450 (CYP) 3A, chronic (taken more than 3 times a week for more than 3 months) use of NSAIDs (use of low-dose aspirin is permitted, as per medical judgement), and/or chronic use of systemic within 8 weeks prior to screening.
  19. Current or prior treatment within 6 months prior to screening with cytotoxic therapy.
  20. Treatment with K+ supplements are not prohibited but should be continuously assessed and monitored throughout the trial.

    Prior/Concurrent Clinical Study Experience

  21. Known to baxdrostat or drugs of the same class, or any of its .
  22. Participation in another clinical study with an IMP administered in the 3 months prior to randomisation in this study Other Exclusions
  23. Participants working shifts (i.e., shifts that comprise working hours at different times on different days) or working night shifts.
  24. Participants who cannot complete the 24-hour ABPM assessment at randomization (as judged by the Principal Investigator).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
286 participants (estimated)

Study arms

  • Experimental
    baxdrostat 2 mg

    2 mg baxdrostat administered orally, once daily (QD)

    Drug: baxdrostat 2mg

  • Placebo comparator
    Placebo 2mg

    2 mg placebo administered orally, once daily (QD)

    Drug: Placebo 2mg

Interventions

  • baxdrostat 2mg tablet administered orally, once daily (QD).

  • DrugPlacebo 2mg

    Placebo 2mg tablet administered orally, once daily (QD).

06

What researchers measure

Primary outcomes

  1. Change from baseline in ambulatory 24-hour average Systolic blood pressure(SBP) at Week 12

    To assess the effect of baxdrostat 2mg versus placebo on ambulatory 24-hour average SBP at 12 weeks

    Time frame: Week12

Secondary outcomes

  1. Change from baseline in ambulatory night-time average Systolic blood pressure(SBP) at Week 12

    To assess the effect of baxdrostat 2mg versus placebo on ambulatory night-time average SBP at 12 weeks

    Time frame: week12

  2. Change from baseline in ambulatory daytime average Systolic blood pressure(SBP) at Week 12

    To assess the effect of baxdrostat 2mg versus placebo on ambulatory daytime average Systolic blood pressure(SBP) at 12 weeks

    Time frame: week12

  3. Change from baseline in seated Systolic blood pressure(SBP) at Week 12

    To assess the effect of baxdrostat 2mg versus placebo on seated SBP at 12 weeks

    Time frame: week12

  4. Percentage achieving ambulatory 24-hour average SBP <130 mmHg at Week 12

    To assess the effect of baxdrostat 2mg versus placebo on achieving ambulatory 24-hour average SBP \<130 mmHg at 12 weeks

    Time frame: week12

  5. Change from baseline in ambulatory 24-hour Diastolic Blood Pressure(DBP) at Week 12

    To assess the effect of baxdrostat 2mg versus placebo on ambulatory 24-hour DBP at 12 week

    Time frame: week12

  6. Change from baseline in ambulatory night-time average DBP at Week 12

    To assess the effect of baxdrostat 2mg versus placebo on ambulatory night-time average DBP at 12 weeks

    Time frame: week12

  7. Change from baseline in ambulatory daytime average DBP at Week 12

    To assess the effect of baxdrostat 2mg versus placebo on ambulatory daytime average DBP at 12 weeks

    Time frame: week12

  8. Change from baseline in seated DBP at Week 12

    To assess the effect of baxdrostat 2mg versus placebo on seated DBP at 12 weeks

    Time frame: week12

  9. Adverse Events (AE)s

    To assess the safety and tolerability of baxdrostat

    Time frame: ICF to safety followup visit-approximately 22 weeks.

  10. Adverse Events of special interest (AESI)s -hyperkalaemia

    To assess the safety and tolerability of baxdrostat

    Time frame: ICF to safety followup visit-approximately 22 weeks.

  11. Serious Adverse Event(SAE)s

    To assess the safety and tolerability of baxdrostat

    Time frame: ICF to safety followup visit-approximately 22 weeks.

  12. Discontinuation of IP due to Adverse Event(DAE)s

    To assess the safety and tolerability of baxdrostat

    Time frame: ICF to safety followup visit-approximately 22 weeks.

  13. Adverse Events of special interest (AESI)s- hyponatraemia

    To assess the safety and tolerability of baxdrostat

    Time frame: ICF to safety followup visit-approximately 22 weeks.

07

Study locations

1 of 51 sites recruiting
  • Research Site
    Beijing, 100029, China
    Recruiting
  • Research Site
    Beijing, 100034, China
    Not yet recruiting
  • Research Site
    Beijing, 100191, China
    Not yet recruiting
  • Research Site
    Beijing, 100730, China
    Not yet recruiting
  • Research Site
    Bengbu, 233004, China
    Not yet recruiting
  • Research Site
    Changchun, 130033, China
    Not yet recruiting
  • Research Site
    Changsha, 410005, China
    Not yet recruiting
  • Research Site
    Chengdu, 610031, China
    Not yet recruiting
  • Research Site
    Chengdu, 610078, China
    Not yet recruiting
  • Research Site
    Chongqing, 400038, China
    Not yet recruiting
  • Research Site
    Foshan, 528300, China
    Not yet recruiting
  • Research Site
    Fuzhou, 350005, China
    Not yet recruiting
  • Research Site
    Fuzhou, 350031, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510100, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510180, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510515, China
    Not yet recruiting
  • Research Site
    Haikou, 570311, China
    Not yet recruiting
  • Research Site
    Hangzhou, 310006, China
    Not yet recruiting
  • Research Site
    Jinan, 250012, China
    Not yet recruiting
  • Research Site
    Jinan, 250021, China
    Not yet recruiting
  • Research Site
    Kunming, 650032, China
    Not yet recruiting
  • Research Site
    Lanzhou, 730030, China
    Not yet recruiting
  • Research Site
    Lu'an, 237005, China
    Not yet recruiting
  • Research Site
    Nanchang, 330006, China
    Not yet recruiting
  • Research Site
    Nanjing, 210029, China
    Not yet recruiting
  • Research Site
    Nanjing, 211103, China
    Not yet recruiting
  • Research Site
    Nanjing, China
    Not yet recruiting
  • Research Site
    Nanning, 530021, China
    Not yet recruiting
  • Research Site
    Ningbo, 315010, China
    Not yet recruiting
  • Research Site
    Qingdao, 266042, China
    Not yet recruiting
  • Research Site
    Shanghai, 200030, China
    Not yet recruiting
  • Research Site
    Shanghai, 200050, China
    Not yet recruiting
  • Research Site
    Shanghai, 200080, China
    Not yet recruiting
  • Research Site
    Shanghai, 200120, China
    Not yet recruiting
  • Research Site
    Shanghai, 310000, China
    Not yet recruiting
  • Research Site
    Shantou, 515041, China
    Not yet recruiting
  • Research Site
    Shenyang, 110016, China
    Not yet recruiting
  • Research Site
    Shenzhen, 518020, China
    Not yet recruiting
  • Research Site
    Shijiazhuang, 050051, China
    Not yet recruiting
  • Research Site
    Suzhou, 215002, China
    Not yet recruiting
  • Research Site
    Taiyuan, 030001, China
    Not yet recruiting
  • Research Site
    Taiyuan, 030032, China
    Not yet recruiting
  • Research Site
    Taizhou, 225300, China
    Not yet recruiting
  • Research Site
    Tianjin, 300121, China
    Not yet recruiting
  • Research Site
    Tianjin, 300457, China
    Not yet recruiting
  • Research Site
    Ürümqi, 830054, China
    Not yet recruiting
  • Research Site
    Wuhan, 430010, China
    Not yet recruiting
  • Research Site
    Wuhan, CN-430022, China
    Not yet recruiting
  • Research Site
    Xi'an, 710114, China
    Not yet recruiting
  • Research Site
    Yinchuan, 750004, China
    Not yet recruiting
  • Research Site
    Zhengzhou, 450003, China
    Not yet recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Feb 2028, 16 months after the start.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 16 months is below that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
Jul 7, 2026
StartActual
Sep 17, 2026
Primary completionEst.
Feb 9, 2028
CompletionEst.
Feb 9, 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
51 sites added — first site in China
Show 51 added (51 China)
  • Research Site · Beijing, China
  • Research Site · Beijing, China
  • Research Site · Beijing, China
  • Research Site · Beijing, China
  • Research Site · Bengbu, China
  • Research Site · Changchun, China
  • Research Site · Changsha, China
  • Research Site · Chengdu, China
  • Research Site · Chengdu, China
  • Research Site · Chongqing, China
  • Research Site · Foshan, China
  • Research Site · Fuzhou, China
  • Research Site · Fuzhou, China
  • Research Site · Guangzhou, China
  • Research Site · Guangzhou, China
  • Research Site · Guangzhou, China
  • Research Site · Haikou, China
  • Research Site · Hangzhou, China
  • Research Site · Jinan, China
  • Research Site · Jinan, China
  • Research Site · Kunming, China
  • Research Site · Lanzhou, China
  • Research Site · Lu'an, China
  • Research Site · Nanchang, China
  • Research Site · Nanjing, China
  • Research Site · Nanjing, China
  • Research Site · Nanjing, China
  • Research Site · Nanning, China
  • Research Site · Ningbo, China
  • Research Site · Qingdao, China
  • …and 21 more on the registry record
Oct 15, 2026
Start date
Sep 30, 2026→Sep 17, 2026 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    51 sites added — first site in China
    Show 51 added (51 China)
    • Research Site · Beijing, China
    • Research Site · Beijing, China
    • Research Site · Beijing, China
    • Research Site · Beijing, China
    • Research Site · Bengbu, China
    • Research Site · Changchun, China
    • Research Site · Changsha, China
    • Research Site · Chengdu, China
    • Research Site · Chengdu, China
    • Research Site · Chongqing, China
    • Research Site · Foshan, China
    • Research Site · Fuzhou, China
    • Research Site · Fuzhou, China
    • Research Site · Guangzhou, China
    • Research Site · Guangzhou, China
    • Research Site · Guangzhou, China
    • Research Site · Haikou, China
    • Research Site · Hangzhou, China
    • Research Site · Jinan, China
    • Research Site · Jinan, China
    • Research Site · Kunming, China
    • Research Site · Lanzhou, China
    • Research Site · Lu'an, China
    • Research Site · Nanchang, China
    • Research Site · Nanjing, China
    • Research Site · Nanjing, China
    • Research Site · Nanjing, China
    • Research Site · Nanning, China
    • Research Site · Ningbo, China
    • Research Site · Qingdao, China
    • …and 21 more on the registry record
    Start date Sep 30, 2026→Sep 17, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07686120
Lead sponsor
AstraZeneca
Collaborators
Tigermed Consulting Co., Ltd
Responsible party
Sponsor
First posted
Jul 7, 2026
Start date
Sep 17, 2026
Primary completion
Feb 9, 2028 (estimated)
Completion
Feb 9, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baxdrostat

Start the discussion